Linked Life Data

12434692

Source:http://linkedlifedata.com/resource/pubmed/id/12434692

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12434692rdf:typepubmed:Citationlld:pubmed
pubmed-article:12434692lifeskim:mentionsumls-concept:C0043015lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C0521018lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C0205265lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C1551362lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C0014282lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C1999244lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C1555582lld:lifeskim
pubmed-article:12434692lifeskim:mentionsumls-concept:C0301869lld:lifeskim
pubmed-article:12434692pubmed:dateCreated2002-11-18lld:pubmed
pubmed-article:12434692pubmed:abstractTextThe UK was the first country to introduce meningococcal serogroup C conjugate vaccination. The vaccine was incorporated into the routine infant immunisation schedule and was offered to all under 18 year olds in a catch-up campaign. The vaccine has been well accepted in infants receiving routine vaccination, with coverage around 89%. Coverage in older children targeted in the catch-up campaign was above 85% up to the age of 14, and was lowest (43%) in 15-17 year olds not in education. The winter of 2000-01 was the first meningococcal season following the offer of the vaccination to all children and adolescents. The incidence of serogroup C disease in the targeted age groups fell by 80%, and the number of deaths in laboratory confirmed cases in 0-19 year olds decreased from 78 to 8 between 1998-99 and 2000-01. The incidence of serogroup B disease in all age groups was slightly higher in 2000-01 than previous years, and there was an increase in the incidence of serogroup C disease in those aged over 20 during the study period, leading to the extension of the vaccination campaign to 20-24 year olds.lld:pubmed
pubmed-article:12434692pubmed:languageenglld:pubmed
pubmed-article:12434692pubmed:citationSubsetIMlld:pubmed
pubmed-article:12434692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12434692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12434692pubmed:statusMEDLINElld:pubmed
pubmed-article:12434692pubmed:authorpubmed-author:KaczmarskiE...lld:pubmed
pubmed-article:12434692pubmed:authorpubmed-author:RamsayM EMElld:pubmed
pubmed-article:12434692pubmed:authorpubmed-author:TrotterC LCLlld:pubmed
pubmed-article:12434692pubmed:ownerNLMlld:pubmed
pubmed-article:12434692pubmed:authorsCompleteYlld:pubmed
pubmed-article:12434692pubmed:pagination220-5lld:pubmed
pubmed-article:12434692pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:12434692pubmed:articleTitleMeningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.lld:pubmed
pubmed-article:12434692pubmed:affiliationImmunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ. ctrotter@phls.org.uklld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12434692lld:pubmed